Guardant Health GH Oncology — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Guardant Health in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Guardant Health's oncology — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Guardant Health's oncology — total revenue?
- Guardant Health (GH) reported oncology — total revenue of $204.95M in Q1 2026.
- How has Guardant Health's oncology — total revenue changed year-over-year?
- Guardant Health's oncology — total revenue increased by 36.1% year-over-year, from $150.56M to $204.95M.
- What is the long-term trend for Guardant Health's oncology — total revenue?
- Over 2 years (2023 to 2025), Guardant Health's oncology — total revenue has grown at a 30.1% compound annual growth rate (CAGR), from $403.88M to $683.6M.
- What does oncology — total revenue mean?
- This metric represents the total gross income generated from the sale of liquid biopsy tests, companion diagnostics, and molecular residual disease testing services within the oncology business unit. It reflects the company's ability to monetize its genomic testing portfolio across clinical and research settings. This revenue stream is a primary indicator of market adoption for precision oncology diagnostic solutions.